Evidence map›Paper›PMID 34912612›Full record

ReviewCureus2021

Bevacizumab and Sinus Venous Thrombosis: A Literature Review.

Vikash Jaiswal, Esha Jain, Gazala Hitawala, Hanyou Loh, Suyog Patel, Pawan Thada, Varsha Nandwana, Shreya Pandey, Jonathan Quinonez, Sidra Naz and 2 more

Registry-linked trialOpen access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06819566 (Prophylactic Endoscopic Variceal Ligation in Patients With High-risk Esophageal Varices Receiving Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06819566 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Prophylactic Endoscopic Variceal Ligation in Patients With High-risk Esophageal Varices Receiving Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma : A Phase II, Multicenter, Single-arm Trial (ESCOAT Trial)

TypeinterventionalSponsorAsan Medical CenterRan2025 to 2029Enrolled44ConditionsHepatocellular Carcinoma, Esophageal Varix, Bleeding Esophageal VaricesArmsEndoscopic variceal ligation (EVL)
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 4 countries.

Vikash JaiswalResearch and Academic Affairs, Larkin Community Hospital, South Miami, USA.
Esha JainMedicine, American University of Antigua, St. John's, ATG.
Gazala HitawalaInternal Medicine, JC Medical Center, Orlando, USA.
Hanyou LohMedicine, National University of Singapore, Singapore, SGP.
Suyog PatelMedicine, B J Medical College, Ahmedabad, IND.
Pawan ThadaResearch, Larkin Community Hospital, South Miami, USA.
Varsha NandwanaMedicine, Lady Hardinge Medical College, Delhi, IND.
Shreya PandeyResearch, Larkin Community Hospital, South Miami, USA.
Jonathan QuinonezNeurology/Osteopathic Neuromuscular Medicine, Larkin Community Hospital, South Miami, USA.
Sidra NazInternal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA.
Joel D SteinOsteopathic Neuromusculoskeletal Manipulative Medicine, Family Medicine, Sports Medicine, Pain Medicine, Lake Erie College of Osteopathic Medicine Bradenton, Bradenton, USA.
Wilson CuevaNeurology, Larkin Community Hospital, South Miami, USA.
Larkin Community Hospital · USAmerican University of Antigua · AGBeth Israel Deaconess Medical Center · USB.J. Medical College · INLady Hardinge Medical College · INNational University of Singapore · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pediatric glioma treatment can be confounded by eloquent anatomical location and pathologic and genetic characteristics. Current literature suggests that the vascular endothelial growth factor (VEGF) inhibitor bevacizumab has been linked to enhancing disease control; however, its safety and effectiveness are unknown. Bevacizumab has been linked with an increased incidence of intratumoral hemorrhage as well as arterial and venous thromboembolism. A rare adverse effect of chemotherapeutic treatment with bevacizumab is sinus venous thrombosis (SVT), with only a few cases reported to date. This review highlights the pathophysiology of bevacizumab, its rare and life-threatening side effect of SVT, and future recommendations.

Indexed as

bevacizumabcerebral sinus venous thrombosisgliomaneurology and critical carepediatrics emergencyvegf inhibitor

Identifiers

PMID34912612
PMCPMC8665695
OpenAlexW3213673634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.